1. NAME OF THE MEDICINAL PRODUCTCombined salmeterol and fluticasone 25 microgram /50 microgram/dose pressurised inhalation.Combined salmeterol and fluticasone 25 microgram /125 microgram/dose pressurised inhalation.Combined salmeterol and fluticasone 25 microgram /250 microgram/dose pressurised inhalation.

2. QUALITATIVE AND QUANTITATIVE COMPOSITION5 micrograms of salmeterol (as salmeterol xinafoate) and 50, 125 or 250 micrograms of fluticasone propionate (delivered from the valve). This is equivalent to 21 micrograms of salmeterol and 44, 110 or 220 micrograms of fluticasone propionate delivered from the actuator (delivered dose).

3. PHARMACEUTICAL FORMPressurised inhalation, suspension. The canister contains a white to off white suspension.

4.Therapeutic indicationsSeretide is indicated in the regular treatment of asthma where use of a combination product (long-acting beta-2-agonist and inhaled corticosteroid) is appropriate: -patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting beta-2-agonist or -patients already adequately controlled on both inhaled corticosteroid and long-acting beta-2-agonist.